Carlo J. Iasella, PharmD, MPH, BCPS is an assistant professor in the Department of Pharmacy and Therapeutics at the School of Pharmacy and a clinical pharmacist specializing in lung transplantation at UPMC Presbyterian Hospital.
Dr. Iasella earned his PharmD at the University of Pittsburgh School of Pharmacy in 2015. He completed a PGY-1 Pharmacy Practice Residency at the University of Pittsburgh Medical Center Presbyterian Hospital, and earned his Master’s in Public Health at the University of Pittsburgh Graduate School of Public Health, focusing on epidemiology and biostatistics. He is completed a two-year fellowship in Clinical Trials and Outcomes Research at the University of Pittsburgh School of Pharmacy where he worked primarily with the clinical and research programs in both lung transplantation and pharmacogenomics.
Dr. Iasella has authored and co-authored several publications in lung transplantation and cardiology. His current research efforts focus on understanding and preventing chronic lung allograft dysfunction, the leading cause of death in lung transplant recipients after the first year, using clinical outcomes analysis of data extracted from the electronic health record, clinical trials, and translational approaches.
Outcomes Research
(Selected)
Iasella CJ, Hoji A, Popescu I, Wei J, Snyder ME, Zhang Y, Xu W, Iouchmanov V, Koshy R, Brown M, Fung M, Langelier C, Lendermon EA, Dugger D, Shah R, Lee J, Johnson B, Golden J, Leard LE, Ellen Kleinhenz M, Kilaru S, Hays SR, Singer JP, Sanchez PG, Morrell MR, Pilewski JM, Greenland JR, Chen K, McDyer JF. Type-1 immunity and endogenous immune regulators predominate in the airway transcriptome during chronic lung allograft dysfunction. Am J Transplant. 2021 Jun;21(6):2145-2160. doi: 10.1111/ajt.16360. Epub 2020 Nov 20. PMID: 33078555; PMCID: PMC8607839.
Iasella CJ, Winstead RJ, Moore CA, Johnson BA, Feinberg AT, Morrell MR, Hayanga JWA, Lendermon EA, Zeevi A, McDyer JF, Ensor CR. Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors. Transplantation. 2018 Jan;102(1):171-177. doi: 10.1097/TP.0000000000001873. PMID: 28691954.
Iasella CJ, Ensor CR, Marrari M, Mangiola M, Xu Q, Nolley E, Moore CA, Morrell MR, Pilewski JM, Sanchez PG, McDyer JF, Zeevi A. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction. J Heart Lung Transplant. 2020 Dec;39(12):1417-1425. doi: 10.1016/j.healun.2020.09.003. Epub 2020 Sep 10. PMID: 32981841.
Ensor CR, Iasella CJ, Harrigan KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-1533. doi: 10.1111/ajt.14723. Epub 2018 Apr 6. PMID: 29513387.
Iasella CJ, Winters SA, Kois A, Cho J, Hannan SJ, Koshy R, Moore CA, Ensor CR, Lendermon EA, Morrell MR, Pilewski JM, Sanchez PG, Kass DJ, Alder JK, Nouraie SM, McDyer JF. Idiopathic pulmonary fibrosis lung transplant recipients are at increased risk for EBV-associated posttransplant lymphoproliferative disorder and worse survival. Am J Transplant. 2020 May;20(5):1439-1446. doi: 10.1111/ajt.15756. Epub 2020 Jan 22. PMID: 31874120; PMCID: PMC8130541.
